Dyax

 

Advancing Novel Biotherapeutics Since 1995®

Investor Relations

Dyax is a biopharmaceutical company focused on developing and commercializing products for unmet medical needs. We currently market a product for the treatment of acute attacks of hereditary angioedema (HAE), a rare genetic disease (to learn more, click here). We also have an investigational drug candidate in development for the prevention of HAE attacks (to learn more, click here).

Both our commercial product and drug candidate in development were identified using Dyax’s proprietary phage display technology. We have broadly licensed this technology and have a portfolio of product candidates being developed by our licensees that we refer to as the Licensing and Funded Research Portfolio (LFRP). This portfolio includes one approved product for which we receive royalties. Additionally, there are multiple product candidates in various stages of clinical development for which we are eligible to receive future milestones and royalties (to learn more, click here).

More »Stock Quote

DYAX (Common Stock)
Exchange NASDAQ (US Dollars)
Price $24.03
Change (%) 0.23 (-0.95)%
Volume 1,305,000
Data as of Jul 30, 2015 4:00 PM ET
Delayed at least 20 minutes. Provided by eSignal.
Refresh Quote

More »Recent Releases

Date Title
Jul 29, 2015 Dyax Corp. Announces Second Quarter 2015 Financial Results
Jul 15, 2015 Dyax Corp. to Host Second Quarter 2015 Earnings Call and Webcast
Jul 7, 2015 Dyax Corp. Receives FDA Breakthrough Therapy Designation for DX-2930 for Prevention of Attacks of Hereditary Angioedema
Jun 8, 2015 Dyax Corp. Presents Phase 1b DX-2930 Data at the 2015 European Academy of Allergy and Clinical Immunology Annual Congress

More »Calendar of Events

Details on upcoming events are not yet available.

More » Event Archives

Jul 29, 2015 Dyax Corp. 2Q 2015 Earnings Call
Jun 1, 2015 Jefferies 2015 Global Healthcare Conference
May 6, 2015 Deutsche Bank 40th Annual Health Care Conference
Apr 29, 2015 Dyax Corp. 1Q 2015 Earnings Call

Featured Financial Reports

Filing Date Title Type Size
Jul 30, 2015 10-Q View HTML View PDF 284.5 KB Add to Briefcase
Dec 31, 2014 2014 Annual Report PDF  963.7 KB Add to Briefcase
Add to Briefcase = add file to Briefcase
 

You are now leaving Dyax.com.

The web site you are about to visit is . It is neither owned nor controlled by Dyax Corp. Dyax is not responsible for the content, products or services on this site.

Do you wish to continue?